GH Research PLC (NASDAQ:GHRS) Receives Consensus Recommendation of “Buy” from Analysts

Shares of GH Research PLC (NASDAQ:GHRS) have received a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have covered the stock in the last year is $32.00.

A number of research firms have recently weighed in on GHRS. Cantor Fitzgerald began coverage on GH Research in a research report on Wednesday, June 4th. They set an “overweight” rating and a $25.00 target price for the company. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of GH Research in a research report on Friday, May 9th. JMP Securities restated a “market outperform” rating and set a $39.00 target price on shares of GH Research in a research report on Tuesday, June 24th. Wall Street Zen upgraded GH Research from a “sell” rating to a “hold” rating in a research report on Saturday, July 5th. Finally, Guggenheim dropped their target price on GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, May 9th.

Institutional Investors Weigh In On GH Research

Institutional investors have recently made changes to their positions in the stock. Two Sigma Investments LP acquired a new stake in shares of GH Research during the fourth quarter worth $117,000. Jefferies Financial Group Inc. acquired a new stake in shares of GH Research during the first quarter worth $8,272,000. Millennium Management LLC acquired a new stake in shares of GH Research during the fourth quarter worth $145,000. BNP Paribas Financial Markets acquired a new stake in shares of GH Research during the fourth quarter worth $44,000. Finally, Northern Trust Corp grew its stake in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after purchasing an additional 8,641 shares during the period. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Stock Performance

Shares of GHRS opened at $12.41 on Monday. The stock has a fifty day moving average price of $13.89 and a two-hundred day moving average price of $12.08. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50. The company has a market cap of $645.67 million, a price-to-earnings ratio of -16.77 and a beta of 0.98.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. As a group, research analysts predict that GH Research will post -0.8 EPS for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).